Spots Global Cancer Trial Database for Study of AZD8931 in Patients With Advanced Solid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of AZD8931 in Patients With Advanced Solid Malignancies
Official Title: A Phase 1, Open-label, Multiple-dose, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8931 in Patients With Advanced Solid Malignancies
Study ID: NCT00637039
Conditions
Interventions
Study Description
Brief Summary: The main purpose of this study is to explore the safety and tolerability of multiple ascending doses (MAD) of AZD8931 in patients with advanced solid malignancies
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Berlin, , Germany
Research Site, Moscow, , Russian Federation
Research Site, St. Petersburg, , Russian Federation
Contact Details
Name: S. Tjulandin
Affiliation: GU Russian Oncology Research Centre
Role: PRINCIPAL_INVESTIGATOR
Name: Serban Ghiorghiu
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
